The downgrade from Overweight to Equal-Weight suggests that Morgan Stanley sees less upside potential in Aflac's stock, which could lead to some selling pressure. However, the increase in price target from $74 to $75 indicates a slightly more optimistic outlook on the stock's value, which could counteract some of the negative sentiment. The net impact on the stock's price in the short term is uncertain, hence the neutral score.